Skin autofluorescence of advanced glycation end products and course of affective disorders in the lifelines cohort study, a prospective investigation
Hagen, J., Sutterland, A.L.,
Schirmbeck, F., Cohn, D.M., Lok, A., Tan, H.L.O., Zwinderman, A.H. &
De Haan, L.Verschenen in Journal of Affective Disorders, 276, 424-432 (2020)
Burying Our Heads in the Sand: The Neglected Importance of Reporting Inter-Rater Reliability in Antipsychotic Medication Trials
Berendsen, S.,
Van, H., Verdegaal, L.M.A., van Tricht, M.J.,
Blankers, M. &
De Haan, L.Verschenen in Schizophrenia Bulletin, Vol. 46 no. 5, 1027-1029 (2020)
But I did not touch nobody!-Patients’ and nurses’ perspectives and recommendations after aggression on psychiatric wards-A qualitative study
Vermeulen, J.M., Doedens, P.R.M., Boyette, L.N.J., Spek, B., Latour, C.H.M.R.N. &
De Haan, L.Verschenen in Journal of Advanced Nursing , Volume75, Issue11, 2845-2854 (2019)
Childhood adversities and psychotic symptoms: The potential mediating or moderating role of neurocognition and social cognition
Mansueto, G., Schruers, K., Cosci, F.,
De Haan, L.,
Schirmbeck, F., GROUP Investigators & van Os, J.
Verschenen in Schizophrenia Research, Volume 206, 183-193 (2019)
Dying too soon: Excess mortality in Severe Mental Illness
De Mooij, L.D.,
Kikkert, M.J., Theunissen, J.,
Beekman, A.T.F.,
De Haan, L.,
Duurkoop, P.W.R.A.,
Van, H. &
Dekker, J.J.M.Verschenen in Frontiers in Psychiatry, Volume 10, 1-10 (2019)
Measuring process indicators and adverse events to assess the quality of care for inpatients with psychosis
Vermeulen, J.M., van Rooijen, G., van Tricht, M.J., van Dijk, M. &
De Haan, L.Verschenen in Journal of Mental Health, Volume 30, Issue 5, 564-570 (2019)
Obsessive-compulsive symptoms in psychotic disorders: longitudinal associations of symptom clusters on between- and within-subject levels
Schirmbeck, F., Konijn, M., Hoetjes, V., Zink, M. &
De Haan, L.Verschenen in European Archives of Psychiatry and Clinical Neuroscience, 269, 245-255 (2019)
Examining the independent and joint effects of molecular genetic liability and environmental exposures in schizophrenia: results from the EUGEI study
Guloksuz, S., Pries, L.K., Delespaul, P., Kenis, G., Luykx, J.J., Lin, B.D.,
De Haan, L., GROUP Researchers & van Os, J.
Verschenen in World Psychiatry, 18(2), 173-182 (2019)
Gender differences of patients at-risk for psychosis regarding symptomatology, drug use, comorbidity and functioning – Results from the EU-GEI study
Menghini-Müller, S., Studerus, E., Ittig, S., Heitz, U., Egloff, L., Andreou, C., Valmaggia, L.R., Kempton, M.J., van der Gaag, M.,
De Haan, L. & et al.
Verschenen in European Psychiatry, 59, 52-59 (2019)
Plasma dopa decarboxylase activity in treatment-resistant recent-onset psychosis patients
van der Pluijm, M., Sutterland, A.L., van Kullenbrog, A.B.P., Zoetekouw, L.,
De Haan, L., Booij, J. & van de Giessen, E.
Verschenen in Therapeutic Advances in Psychopharmacology, 9, 1-7 (2019)
Premorbid Adjustment and IQ in Patients With First-Episode Psychosis: A Multisite Case-Control Study of Their Relationship With Cannabis Use
Ferraro, L., La Cascia, C., Quattrone, D., Sideli, L., Matranga, D., Cappucio, V., WP2 EU-GEI Group,
De Haan, L. & di Forti, M., et al.
Verschenen in Schizophrenia Bulletin, Volume 46, Issue 3, 517–529 (2019)
Use of Natural Language Processing to identify Obsessive Compulsive Symptoms in patients with schizophrenia, schizoaffective disorder or bipolar disorder
Chandran, D., Robbins, D.A., Chang, C.K., Shetty, H., Sanyal, J., Downs, J., Fok, M., Ball, M., Jackson, R., Stewart, R., Cohen, R., Vermeulen, J.M.,
Schirmbeck, F.,
De Haan, L. & Hayes, R.
Verschenen in Scientific Reports, 9, 14146, 1-7 (2019)
Clozapine and Long-Term Mortality Risk in Patients With Schizophrenia: A Systematic Review and Meta-analysis of Studies Lasting 1.1-12.5 Years
Vermeulen, J.M., van Rooijen, G., van de Kerkhof, M.P.J., Sutterland, A.L., Correll, C.U. &
De Haan, L.Verschenen in Schizophrenia Bulletin, Volume 45, Issue 2, 315-329 (2019)
Cognitive behavioral therapy for social activation in recent-onset psychosis: Randomized controlled trial
Pos, K., Franke, N., Smit, F., Wijnen, B.F.M., Staring, A.B.P., van der Gaag, M., Meijer, C.,
De Haan, L., Velthorst, E. &
Schirmbeck, F.Verschenen in Journal of Consulting and Clinical Psychology, 87 (2), 151–160 (2019)
Increased serum levels of leptin and insulin in both schizophrenia and major depressive disorder: A cross-disorder proteomics analysis
Cakici, N., Bot, M., Lamers, F., Janssen, T., van der Spek, P.J.,
De Haan, L., Bahn, S., Penninx, B.W.J.H. & van Beveren, N.J.M.
Verschenen in European Neuropsychopharmacology, Volume 29, Issue 7, 835-846 (2019)
Comparison of erythrocyte omega-3 index, fatty acids and molecular phospholipid species in people at ultra-high risk of developing psychosis and healthy people
Alqarni, A., Todd, W.M., McGorry, P.D., Nelson, B., Markulevm C., Yuen, H.P., Schäfer, M.R.,
De Haan, L., Meyera, B.J. & et. al.
Verschenen in Schizophrenia Research, Volume 226, 44-51 (2019)
Individualized Prediction of Transition to Psychosis in 1,676 Individuals at Clinical High Risk: Development and Validation of a Multivariable Prediction Model Based on Individual Patient Data Meta-Analysis
Malda, A., Boonstra, N., Barf, H., de Jong, S., Aleman, A., Addington, J.,
De Haan, L., Pijnenborg, G.H.M. & et al.
Verschenen in Frontiers in Psychiatry, 10, 345 (2019)
Designing and Testing of a Health-Economic Markov Model for Prevention and Treatment of Early Psychosis
Wijnen, B.F.M., Thielen, F.W., Konings, S., Feenstra, T., van der Gaag, M., Veling, W.,
De Haan, L., Ising, H., Hiligsman, M., Evers, S.M.A.A., Smit, F. & Lokkerbol, J.
Verschenen in Expert Review of Pharmacoeconomics & Outcomes Research, Volume 20, 2020, Issue 3, 269-279 (2019)
Smoking and the risk for bipolar disorder: evidence from a bidirectional Mendelian randomisation study
Vermeulen, J.M., Wootton, R.E., Treur, J.L., Sallis, H.M., Jones, H.J., Zammit, S., van den Brink, W., Goodwin, G.M.,
De Haan, L. & Munafo, M.R.
Verschenen in The British Journal of Psychiatry, Volume 218 , Issue 2, 88 - 94 (2019)
